Literature DB >> 19762387

Catastrophic antiphospholipid syndrome in a patient with Down syndrome.

Gabriela Medina1, Consuelo Calleja, Massiel Morán, Olga Vera-Lastra, Luis J Jara.   

Abstract

We report a patient with Down syndrome, under treatment with carbamazepine, levopromazine and clonazepam. After urinary infection he developed glans necrosis requiring excision of prepuce. Six hours post surgery he presented right-hand ischemia followed by arterial and venous thrombosis of the right thoracic extremity. Later, he progressed to a compartment syndrome and presented ischemia of toes. All the clinical manifestations developed over a week. Anticardiolipin (aCL) antibodies, lupus anticoagulant and perinuclear antineutrophil antibodies were positive. Anticoagulant and immunosuppressive treatment were initiated. Owing to the failure of both treatments, the patient underwent amputation of right hand and a toe. Histopathology revealed recent and old thrombosis of medium- and small-sized vessels without vasculitis. Diagnosis of catastrophic antiphospholipid syndrome (CAPS) was made. At present, the patient continues on oral anticoagulants, IgG aCL remains positive, and no further episodes of thromboses have been observed after 4 years of follow-up. To our knowledge, this is the first case of CAPS in a patient with Down syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762387     DOI: 10.1177/0961203309105878

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  2 in total

Review 1.  Systematic review of case reports of antiphospholipid syndrome following infection.

Authors:  N Abdel-Wahab; M A Lopez-Olivo; G P Pinto-Patarroyo; M E Suarez-Almazor
Journal:  Lupus       Date:  2016-04-07       Impact factor: 2.911

2.  Progressive Venous Thrombosis in an 18-Year-Old Man with Down Syndrome.

Authors:  Yan Lin; Lin Ma; Wen-Jing Jiang; Yi-Ming Liu
Journal:  Chin Med J (Engl)       Date:  2018-10-20       Impact factor: 2.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.